<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00617968</url>
  </required_header>
  <id_info>
    <org_study_id>XRP6976D_2502</org_study_id>
    <nct_id>NCT00617968</nct_id>
  </id_info>
  <brief_title>GETNA2 Neoadj. TAX+Femara vs Femara in g I/II Breast Cancer</brief_title>
  <official_title>A Multicenter, Randomized, Open-label, Phase II Study to Evaluate the Efficacy and Safety of Neoadjuvant Treatment Consisting of Either a Docetaxel - Letrozole Combination or Letrozole Alone in Women Over 60 Years of Age Suffering From Grade I or II Operable Hormone Receptor-positive Breast Tumor.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Sanofi</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Sanofi</source>
  <brief_summary>
    <textblock>
      Primarily to evaluate the rates of clinical and radiological response in the 2 groups.
      Secondarily rate of histological response.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>October 2003</start_date>
  <completion_date type="Actual">June 2005</completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Rate of clinical and radiological response evaluated according to RECIST criteria</measure>
    <time_frame>During the study conduct</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Rate of histological response</measure>
    <time_frame>During the study conduct</time_frame>
  </secondary_outcome>
  <enrollment type="Actual">5</enrollment>
  <condition>Breast Neoplasms</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>DOCETAXEL</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Female patients with breast cancer histologically proven by microbiopsy (14G or 16G)
             enabling confirmation of the diagnosis, and evaluation of the histological prognostic
             grade, hormonal receptors and HER2 status.

          -  Tumor T2 or T3, non-metastasized, non-inflammatory, unilateral

          -  Clinically or radiologically measurable lesion greater than 2 cm (ultrasound and/or
             mammogram)

          -  Receptors RE+ and/or RP+ (positive status determined according to the criteria of the
             investigating centers)

          -  HER 2 / neu status of 0, 1+ or 2+ in immunohistochemistry

          -  Histological grade I or II

          -  Menopausal patients aged greater than or equal to 60 years

          -  Patients with ECOG PS greater than or equal to 2

          -  Satisfactory hematological, hepatic and renal functions:

          -  Hemoglobin greater than or equal to 10 g/dL

          -  Platelet count greater than or equal to 100x109/L

          -  Polynuclear neutrophil count greater than 1.5x109/L

          -  Creatinine less than or equal to â‰¤ 1.5 ULN

          -  AST/ALT less than or equal to 1.5 ULN

          -  Alkaline phosphatases less than or equal to 2.5 ULN

          -  Patients able to be followed throughout the study

          -  Patient's consent obtained.

        Exclusion Criteria:

          -  Inflammatory or T4 breast cancer

          -  T1 tumor

          -  Patients whose tumor is deemed by the doctor to be difficult to evaluate

          -  Tumor that is metastatic from the outset (M1) or locally advanced and inoperable from
             the outset

          -  RE and RP receptors negative or unknown

          -  HER 2/neu positive at 3 +

          -  Non-menopausal patients

          -  Surgical biopsy and/or ganglion dissection before neoadjuvant treatment

          -  Significant poorly controlled cardiac disorders, such as unstable angina pectoris,
             poorly controlled heart failure, arrhythmia requiring treatment, or myocardial
             infarction within the last 3 months

          -  Cardiovascular, hepatic, neurological or endocrine disease, or other major systemic
             disease that makes it difficult to conduct the protocol or to interpret the results

          -  Previous history of cancer that occurred within the last 10 years, with the exception
             of cervical cancers and basocellular skin cancers that were properly treated

          -  Allergy to polysorbate 80

          -  Hypersensitivity to docetaxel

          -  Participation in another clinical trial with one of the study medicinal products
             during the 30 days prior to entry in the study

          -  Patients who are unable to undergo medical monitoring for geographical, social or
             psychological reasons
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>60 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Nathalie BILLON</last_name>
    <role>Study Director</role>
    <affiliation>Sanofi</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Sanofi-Aventis</name>
      <address>
        <city>Paris</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>September 2009</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>February 6, 2008</study_first_submitted>
  <study_first_submitted_qc>February 6, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 18, 2008</study_first_posted>
  <last_update_submitted>September 1, 2009</last_update_submitted>
  <last_update_submitted_qc>September 1, 2009</last_update_submitted_qc>
  <last_update_posted type="Estimate">September 2, 2009</last_update_posted>
  <responsible_party>
    <name_title>Nathalie Billon/Study Director</name_title>
    <organization>sanofi-aventis</organization>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Breast Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Docetaxel</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

